Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda

Sylvia Kusemererwa, Andrew Abaasa, Anita Kabarambi, Martin Onyango, Joseph Okello Mugisha, Sylvia Kusemererwa, Andrew Abaasa, Anita Kabarambi, Martin Onyango, Joseph Okello Mugisha

Abstract

Objectives: Participation in HIV prevention trials could trigger risk compensation among participants. We evaluated potential risk compensation following use of a vaginal ring microbicide by women in a phase III trial in southwestern Uganda.

Methods: We used markers of sexual risk behaviour documented on standardised questionnaires, tested for STIs at baseline and quarterly for 2 years. Risk compensation was defined as a significant increase (trend p<0.05) in the proportion of women reporting risky sexual behaviour or a diagnosed STI between baseline and end of follow-up.

Results: Between September 2013 and December 2016, 197 women (active arm: n=132 and placebo: n=65) were enrolled at the Masaka site. There were decreases in all markers of sexual risk behaviour with statistically significant decreases in only the proportion of women reporting ≥2 sexual partners, p=0.026 and those diagnosed with Trichomonas vaginalis p<0.001 and or Neisseria gonorrhoeae p<0.001 CONCLUSIONS: No evidence of risk compensation was observed in this trial.

Trial registration number: NCT01539226.

Keywords: HIV; sexual behaviour; vaginal microbicides; women.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study profile of women screened and enrolled into a phase III microbicide trial in southwestern Uganda (September 2013–December 2014).

References

    1. UNAIDS . Factsheet: global AIDS update. 2019: UNAIDS Geneva, 2019. Available: [Accessed 27 Jun 2019].
    1. Unaids GH, statistics A. 2018 fact sheet, 2019, 2019. Available: [Accessed 27 Jun 2019].
    1. UNAIDS . Women and HIV — a spotlight on adolescent girls and young women: UNAIDS, 2019. Available: [Accessed 27 Jun 2019].
    1. Sheth AN, Rolle CP, Gandhi M. Hiv pre-exposure prophylaxis for women. J Virus Erad 2016;2:149–55. 10.1016/S2055-6640(20)30458-1
    1. Marrazzo JM, Ramjee G, Richardson BA, et al. . Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med 2015;372:509–18. 10.1056/NEJMoa1402269
    1. Nel A, van Niekerk N, Kapiga S, et al. . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med 2016;375:2133–43. 10.1056/NEJMoa1602046
    1. Baeten JM, Palanee-Phillips T, Brown ER, et al. . Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med Overseas Ed 2016;375:2121–32. 10.1056/NEJMoa1506110
    1. Cassell MM, Halperin DT, Shelton JD, et al. . Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006;332:605–7. 10.1136/bmj.332.7541.605
    1. Eaton LA, Kalichman SC. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007;4:165–72. 10.1007/s11904-007-0024-7
    1. Hogben M, Liddon N. Disinhibition and risk compensation: scope, definitions, and perspective. Sex Transm Dis 2008;35:1009. 10.1097/OLQ.0b013e31818eb752
    1. Riess TH, Achieng' MM, Otieno S, et al. . "When I was circumcised I was taught certain things": risk compensation and protective sexual behavior among circumcised men in Kisumu, Kenya. PLoS One 2010;5:e12366. 10.1371/journal.pone.0012366
    1. Richens J, Imrie J, Copas A. Condoms and seat belts: the parallels and the lessons. Lancet 2000;355:400–3. 10.1016/S0140-6736(99)09109-6
    1. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004;292:224–36. 10.1001/jama.292.2.224
    1. Kong X, Kigozi G, Nalugoda F, et al. . Assessment of changes in risk behaviors during 3 years of posttrial follow-up of male circumcision trial participants uncircumcised at trial closure in Rakai, Uganda. Am J Epidemiol 2012;176:875–85. 10.1093/aje/kws179
    1. Marcus JL, Glidden DV, Mayer KH, et al. . No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One 2013;8:e81997. 10.1371/journal.pone.0081997
    1. Wingood GM, Dunkle K, Camp C, et al. . Racial differences and correlates of potential adoption of preexposure prophylaxis: results of a national survey. J Acquir Immune Defic Syndr 2013;63 Suppl 1:S95. 10.1097/QAI.0b013e3182920126
    1. Guest G, Shattuck D, Johnson L, et al. . Acceptability of PreP for HIV prevention among women at high risk for HIV. J Womens Health 2010;19:791–8. 10.1089/jwh.2009.1576
    1. Koechlin FM, Fonner VA, Dalglish SL, et al. . Values and preferences on the use of oral pre-exposure prophylaxis (PreP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav 2017;21:1325–35. 10.1007/s10461-016-1627-z
    1. Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007;4:165–72. 10.1007/s11904-007-0024-7
    1. Milam J, Jain S, Dubé MP, et al. . Sexual risk compensation in a pre-exposure prophylaxis demonstration study among individuals at risk of HIV. J Acquir Immune Defic Syndr 2019;80:e9–13. 10.1097/QAI.0000000000001885
    1. Newcomb ME, Moran K, Feinstein BA, et al. . Pre-Exposure prophylaxis (PreP) use and condomless anal sex: evidence of risk compensation in a cohort of young men who have sex with men. J Acquir Immune Defic Syndr 2018;77:358. 10.1097/QAI.0000000000001604
    1. Ruzagira E, Wandiembe S, Abaasa A, et al. . Prevalence and incidence of HIV in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda. PLoS One 2011;6:e20684. 10.1371/journal.pone.0020684
    1. Kusemererwa S, Abaasa A, Onyango M, et al. . Contraceptive preference among women at risk of HIV acquisition in a preparatory screening study for a phase III microbicide trial in South Western Uganda. AIDS Behav 2018;22:131–8. 10.1007/s10461-018-2177-3
    1. STD Control Unit of the STD/AIDS Control programme . Ministry of health U. Uganda national guidelines for the syndromic management of sexually transmitted infections 2010.
    1. Control CfD, Prevention . Sexually transmitted diseases treatment guidelines, 2010. Ann Emerg Med 2011;58:67–8. 10.1016/j.annemergmed.2011.04.006
    1. Guest G, Shattuck D, Johnson L, et al. . Changes in sexual risk behavior among participants in a PreP HIV prevention trial. Sex Transm Dis 2008;35:1002–8.
    1. Peterson L, Taylor D, Roddy R, et al. . Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007;2:e27. 10.1371/journal.pctr.0020027
    1. Liu AY, Vittinghoff E, Chillag K, et al. . Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr 2013;64:87–94. 10.1097/QAI.0b013e31828f097a
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012;367:423–34. 10.1056/NEJMoa1110711
    1. Baeten JM, Donnell D, Ndase P, et al. . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med Overseas Ed 2012;367:399–410. 10.1056/NEJMoa1108524
    1. Van Damme L, Corneli A, Ahmed K, et al. . Preexposure prophylaxis for HIV infection among African women. N Engl J Med Overseas Ed 2012;367:411–22. 10.1056/NEJMoa1202614
    1. Gray RH, Kigozi G, Serwadda D, et al. . Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657–66. 10.1016/S0140-6736(07)60313-4
    1. Mattson CL, Campbell RT, Bailey RC, et al. . Risk compensation is not associated with male circumcision in Kisumu, Kenya: a multi-faceted assessment of men enrolled in a randomized controlled trial. PLoS One 2008;3:e2443. 10.1371/journal.pone.0002443
    1. Bartholow BN, Buchbinder S, Celum C, et al. . Hiv sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005;39:90–101. 10.1097/01.qai.0000143600.41363.78
    1. Grund JM, Hennink MM. A qualitative study of sexual behavior change and risk compensation following adult male circumcision in urban Swaziland. AIDS Care 2012;24:245–51. 10.1080/09540121.2011.596516
    1. McCormack S, Ramjee G, Kamali A, et al. . PRO2000 vaginal gel for prevention of HIV-1 infection (microbicides development programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010;376:1329–37. 10.1016/S0140-6736(10)61086-0
    1. van der Straten A, Cheng H, Minnis AM. Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwe. J Int AIDS Soc 2010;13:39. 10.1186/1758-2652-13-39
    1. Marlow HM, Tolley EE, Weaver MA, et al. . Changes in condom use during a microbicide clinical trial in Pune, India. AIDS Care 2012;24:539–43. 10.1080/09540121.2011.630343
    1. Ochako R, Okal J, Kimetu S, et al. . Female sex workers experiences of using contraceptive methods: a qualitative study in Kenya. BMC Womens Health 2018;18:105. 10.1186/s12905-018-0601-5
    1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. . Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168–74. 10.1126/science.1193748

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel